Journal of Clinical and Aesthetic Dermatology

Ingenol Mebutate Topical Gel 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/754617

Contents of this Issue

Navigation

Page 10 of 11

S11 JCAD journal of clinical and aesthetic dermatology November 2016 • Volume 9 • Number 11 Robinson JK, Ross M, et al, eds. Cancer of the Skin, 2nd ed. Philadelphia: Elsevier-Saunders; 2011;497–507. 21. Lebwohl M, Sohm S. Ingenol mebutate (ingenol 3-angelate, PEP005): focus on its uses in the treatment of nonmelanoma skin c ancer. Exp Rev Dermatol. 2012;7(2):121–128. 22. Markowitz O, Schwartz M, Feldman E, et al. Defining field cancerization of the skin using optical coherence tomography imaging to detect and monitor actinic keratosis in ingenol mebutate 0.015%-treated patients. J Clin Aesthet Dermatol. 2016;9(5):18– 25. 23. Spelman L, Rosen R, Knudsen KM, et al. Ingenol mebutate with full occlusion effectively treats superficial BCC. Poster presentation. EADO Congress; Vinius, Lithuania; May 9, 2014. 24. Freeman M, Rosen R, Zibert JR, et al. Ingenol mebutate gel topically applied under occlusion to superficial basal cell carcinoma is efficacious compared with marginal effect in seborrheic keratosis (Poster 7934). Presented at the 72nd Annual American Academy of Dermatology Meeting, Denver, Colorado, March 21–25, 2014. 25. Siller G, Rosen R, Freeman M, et al. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Austral J Dermatol. 2010;51:99–105. 26. Bettencourt MS. Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%. Clin Cosmet Investig Dermatol. 2016;16(9):205–209. 27. Ramsay JR, Suhrbier A, Aylward JH, et al. The sap of Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol. 2011;164:633–636. 28. Alston D, Chow M. Ingenol mebutate gel 0.015% for the topical treatment of nodular basal cell carcinoma. Poster presented at Fall Clinical Dermatology Conference, January 2015. 29. Salleras Redonnet M, Quintana Codina M. Ingenol mebutate gel for the treatment of Bowen's disease: a case report of 3 patients. Dermatol Ther. 2016;29(4):236–239. 30. Barrado Solis N, Moles Povedo P, Lloret Ruiz C, et al. Ingenol m ebutate gel treatment for actinic cheilitis: report of four cases. Dermatol Ther. 2014;29:1–3. 31. Schopf RE. Condyloma accuminata: novel treatment by topical ingenol mebutate (abstract 603). J Investig Dermatol. 2014; 134:S105. 32. Scopf RE. Ingenol mebutate is effective against anogenital warts— a case series in 17 patients. J Eur Acad Dermatol Venereol. 2016;30(6):1041–1043. 33. Kim C, Hashemi P, Caglia M, et al. Treatment of imiquimod- resistant epidermoplasia verruciformis with ingenol mebutate. J Drugs Dermatol. 2016;15(3):350–352. 34. Imtiaz A. Viral warts. In: Lebwohl MG, Heymann WR, Berth- Jones J, et al. Treatment of Skin Disease: Comprehensive Therapeutic Strategies, 3rd ed. Philadelphia: Saunders-Elsevier; 2010;770–775. 35. Javed S, Tyring SK. Treatment of molluscum contagiosum with ingenol mebutate. J Am Acad Dermatol. 2014;70:e105. 36. Kindem S, Serra-Guillen C, Sorni G, et al. Treatment of porokeratosis of Mibelli with ingenol mebutate: a possible new therapeutic option. JAMA Dermatology. Published online November 19, 2014 (jamadermatology.com):E1–E2. 37. De Felice B, Guida M, Boccia L, et al. Ingenol mebutate treatment of keloids. BMC Res Notes. 2015;8:466. 38. Grandi V, Delfino C, Pimpinelli N. Ingenol mebutate in the treatment of hydroxyurea-induced squamous dysplasia: a single centre experience. J Eur Acad Dermatol Venereol. 2016;30(7): 1129–1132. Dr. Del Rosso is a consultant, researcher, and speaker for Leo Pharma, Inc. He also is a consultant, researcher, and/or speaker for Aqua/Amirall, Bayer Dermatology, BioPharmX, Celgene, Cutanea, Dermira, Ferndale, Foamix, Galderma, Genentech, Johnson & Johnson, Novan, Novartis, Pharmaderm, Promius, Sebacia, SunPharma, Taro Pharmaceuticals, Unilever, and Valeant. The content of this article was developed and written solely by the author. Cover photo: Reprinted with permission from: Siller G, Rosen R, Freeman M, et al. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Austral J Dermatol. 2010;51:99–105.

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Ingenol Mebutate Topical Gel 2016